Cerus Corporation

Other

University of California

Baxter International Inc.

Diamond Scientific Company

Steritech, Inc.

Gary P. Wiesehahn

Laurence Corash

Lily Lin

Jean Marc Payrat

Elan Weiner

Richard Benjamin

Stephen T Isaacs

George D Cimino

Gary P Wiesehahn

Johannes Vermeij

Marc Payrat

Melody Holtan

John Tessman

Provided herein are compositions and kits including a pathogen-inactivated cryoprecipitate suitable for infusion into a subject at least 1 day after thawing. The methods are useful in the efficient preparation of cryoprecipitates with desirable characteristics, including pathogen-inactivated cryoprecipitates that are suitable for infusion into a subject at least 1 day after thawing.

Cryoprecipitate compositions and methods of preparation thereof

Provided herein are pathogen-inactivated plasma compositions and methods for treating a disease or condition using pathogen-inactivated plasma compositions.

Plasma compositions and methods of use thereof

Synthetic platelet storage media is disclosed for use with blood preparations intended for in vivo use. The synthetic platelet storage media is prepared by providing sodium chloride, sodium citrate, sodium acetate and sodium phosphate, and formulating in water 45-120 mM sodium chloride, 5-15 mM sodium citrate, 20-40 mM sodium acetate and 20-30 mM sodium phosphate.

Synthetic platelet storage media formulation

Synthetic media formulations are disclosed for use with blood preparations intended for in vivo use, including synthetic media formulations to be employed in conjunction with the photodecontamination of platelets.

Synthetic media for blood components

Methods of photodecontamination are described which employ phosphate buffered aqueous solutions. Blood products comprising plasma are diluted with these solutions and treated with psoralen.

Methods of photodecontamination using synthetic media

Synthetic media formulations are disclosed for use with blood preparations intended for in vivo use, including essentially magnesium free synthetic media formulations to be employed in conjunction with the photodecontamination of platelets.

Methods are disclosed for photodecontamination to inactivate microorganisms in platelet preparations and for removal of psoralen after photodecontamination. Removal is achieved by contacting the psoralen with a psoralen-binding polymer.

Proralen inactivation of microorganisms and psoralen removal

Intravenous administration of 8-methoxypsoralen is disclosed, and more specifically intravenous administration of 8-methoxypsoralen-blood preparations, including platelets. Random donor platelet bags are treated, stored and pooled prior to transfusion.

Intravenous administration of psoralen

Synthetic media formulations are disclosed for use with blood preparations intended for in vivo use, including synthetic media formulations to be employed in conjunction with the photodecontamination of platelets using 8-methoxypsoralen.

Synthetic media compositions for inactivating bacteria and viruses in

Biological compositions are freed of functional polynucletides by treatment of the biological composition with psoralen derivatives under irradiation conditions in which the proteins retain their original physiological activities and any polynucleotide present is rendered inactive. More specifically blood components are decontaminated of viruses by the addition of psoralen and irradiation and thereafter adding glucose.

Growing community of inventors

San Francisco, CA, United States of America

Laurence Corash